8-K: Calidi Biotherapeutics Implements 1-for-10 Reverse Stock Split

Calidi Biotherapeutics has executed a 1-for-10 reverse stock split, effective July 15, 2024, to consolidate its shares.

Summary

• Calidi Biotherapeutics enacted a 1-for-10 reverse stock split of its common stock.
• The reverse stock split was approved by stockholders at a special meeting on June 6, 2024.
• The reverse stock split became effective on July 15, 2024, at 12:01 a.m. Eastern Time.
• Every ten shares of common stock were combined into one share.
• Fractional shares resulting from the split were rounded up to the next whole share.
• The total number of authorized shares remains unchanged at 330,000,000.
• Adjustments were made to stock options and shares reserved for future issuance under the 2023 Equity Incentive Plan.
• The common stock began trading on a split-adjusted basis on July 15, 2024, under the symbol CLDI.
• The company's warrants continue to trade under the symbol CLDI WS.
• The new CUSIP number for the common stock is 320703309.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reverse stock split, which is often a sign of financial challenges. However, the action was expected and approved by shareholders.

Positives

• The reverse stock split was approved by shareholders, indicating support for the company's strategy.
• The company has taken action to potentially improve its stock price and appeal to a broader range of investors.

Negatives

• A reverse stock split is often seen as a sign of a struggling company, which may negatively impact investor sentiment.

Risks

• The reverse stock split may not achieve the desired effect of increasing the stock price.
• The company's stock price may continue to decline despite the reverse stock split.
• There is a risk that the company may need to undertake further capital raising activities in the future.

Industry Context

Reverse stock splits are a common corporate action for companies seeking to increase their stock price and maintain listing requirements. This action is not uncommon in the biotechnology sector, where companies often face challenges in maintaining share price levels.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies with low share prices, particularly in the biotech industry.
• Many companies in similar situations have used reverse stock splits to regain compliance with exchange listing requirements.
• For example, companies like Agenus and Ocugen have also undertaken reverse stock splits to manage their share price.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• The reverse stock split may impact the perceived value of the company by the market.

Key Dates

Keywords

reverse stock split, common stock, stock options, share consolidation, Calidi Biotherapeutics, CLDI, CLDI WS